Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTBVAC Phase 1b/2a in Adults with/without LTBI
NCT02933281Phase 2Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- May 2018
- Primary completion
- Sep 2021
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mtbvac in Tuberculosis (TB) (9 arms), sponsored by International AIDS Vaccine Initiative. Primary endpoint: Safety and reactogenicity. Started May 2018; status: completed.
02
Drugs
mtbvac
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02933281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933281.